About marker therapeutics - MRKR
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.
MRKR At a Glance
Marker Therapeutics, Inc.
2450 Holcombe Boulevard
Houston, Texas 77021
| Phone | 1-713-400-6400 | Revenue | 3.55M | |
| Industry | Biotechnology | Net Income | -12,163,620.00 | |
| Sector | Health Technology | Employees | 5 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
MRKR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 6.432 |
| Price to Book Ratio | 1.479 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.464 |
| Enterprise Value to Sales | 1.627 |
| Total Debt to Enterprise Value | N/A |
MRKR Efficiency
| Revenue/Employee | 709,333.80 |
| Income Per Employee | -2,432,724.00 |
| Receivables Turnover | 2.59 |
| Total Asset Turnover | 0.173 |
MRKR Liquidity
| Current Ratio | 8.386 |
| Quick Ratio | 8.386 |
| Cash Ratio | 7.494 |
MRKR Profitability
| Gross Margin | N/A |
| Operating Margin | -350.675 |
| Pretax Margin | -343.386 |
| Net Margin | -342.959 |
| Return on Assets | -59.199 |
| Return on Equity | -68.808 |
| Return on Total Capital | -72.416 |
| Return on Invested Capital | -68.808 |
MRKR Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |